Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   5/06/2026
163,88 USD (-2,07%)
(-2,07%)   5/06/2026

8 juni 2026 · Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities · Persbericht

3 juni 2026 · Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 · Persbericht

26 mei 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in June · Persbericht

18 mei 2026 · Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules · Persbericht

18 mei 2026 · Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics · Persbericht

6 mei 2026 · Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia · Persbericht

5 mei 2026 · Neurocrine Biosciences Reports First-Quarter 2026 Financial Results · Persbericht

5 mei 2026 · Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 · Persbericht

4 mei 2026 · Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment · Persbericht

4 mei 2026 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist · Persbericht

1 mei 2026 · Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia · Persbericht

29 april 2026 · Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale · Persbericht

22 april 2026 · Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia · Persbericht

14 april 2026 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results · Persbericht

14 april 2026 · Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR · Persbericht

6 april 2026 · Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio · Persbericht

26 maart 2026 · Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings · Persbericht

17 maart 2026 · Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer · Persbericht

10 maart 2026 · Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum · Persbericht

6 maart 2026 · BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) · Persbericht

Mijn selecties